Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation...
Main Authors: | Nan Yan, Na Wang, Peiling Zhang, Gaoxiang Wang, Xia Mao, Dan Peng, Dong Kuang, Liting Chen, Li Zhu, Jianfeng Zhou, Yicheng Zhang, Yang Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/full |
Similar Items
-
Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders
by: Akihisa Sawada, et al.
Published: (2018-11-01) -
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
by: Rohit Bishnoi, et al.
Published: (2017-09-01) -
Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients
by: Tinelli Carmine, et al.
Published: (2011-09-01) -
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
by: Thomas Mika, et al.
Published: (2019-12-01) -
CASE 2–2012: a 57-Year-Old Woman with Post-Transplant Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation for Primary Myelofibrosis
by: Milan Košťál, et al.
Published: (2012-01-01)